Abstract： The overall prognosis of differentiated thyroid cancer is good, but a small number of patients will still develop local recurrence and distant metastasis, and lose iodine uptaking ability in the initial or treatment process, becoming radioactive iodine-refractory differentiated thyroid carcinoma (RAIR-DTC), with a poor prognosis. Treatment options for RAIR-DTC patients are limited with poor results, and restoration of iodine uptaking capacity in RAIR-DTC through pharmacological promotion of redifferentiation is one of the important strategies for treatment.